Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study
Carregando...
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
FERRATA STORTI FOUNDATION
Autores
VERHOEF, Gregor
ROBAK, Tadeusz
HUANG, Huiqiang
PYLYPENKO, Halyna
SIRITANARATKUL, Noppadol
DRACH, Johannes
MAYER, Jiri
OKAMOTO, Rumiko
PEI, Lixia
Citação
HAEMATOLOGICA, v.102, n.5, p.895-902, 2017
Resumo
In the phase 3 LYM-3002 study comparing intravenous VR-CAP with R-CHOP in patients with newly-diagnosed, measurable stage II-IV mantle cell lymphoma, not considered or ineligible for transplant, the median progression-free survival was significantly improved with VR-CAP (24.7 versus 14.4 months with R-CHOP; P<0.001). This post-hoc analysis evaluated the association between the improved outcomes and quality of responses achieved with VR-CAP versus R-CHOP in LYM-3002. Patients were randomized to six to eight 21-day cycles of VR-CAP or R-CHOP. Outcomes included progression-free survival, duration of response (both assessed by an independent review committee), and time to next anti-lymphoma treatment, evaluated by response (complete response/unconfirmed complete response and partial response), MIPI risk status, and maximum reduction of lymph-node measurements expressed as the sum of the product of the diameters. Within each response category, the median progression-free survival was longer for patients given VR-CAP than for those given R-CHOP (complete response/unconfirmed complete response: 40.9 versus 19.8 months; partial response: 17.1 versus 11.7 months, respectively); similarly, the median time to next anti-lymphoma treatment was longer among the patients given VR-CAP than among those treated with R-CHOP (complete response/unconfirmed complete response: not evaluable versus 26.6 months; partial response: 35.3 versus 24.3 months). Within the complete/unconfirmed complete and partial response categories, improvements in progression-free survival, duration of response and time to next anti-lymphoma treatment were more pronounced in patients with low- and intermediate-risk MIPI treated with VR-CAP than with R-CHOP. In each response category, more VR-CAP than R-CHOP patients had a sum of the product of the diameters nadir of 0 during serial radiological assessments. Results of this post-hoc analysis suggest a greater duration and quality of response in patients treated with VR-CAP in comparison with those treated with R-CHOP, with the improvements being more evident in patients with low-and intermediate-risk MIPI. LYM-3002 ClinicalTrials.gov: NCT00722137.
Palavras-chave
Referências
- Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403
- Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800
- Dreyling M, 2013, ANN ONCOL, V24, P857, DOI 10.1093/annonc/mds643
- Dreyling M, 2015, NAT REV CLIN ONCOL, V12, P377, DOI 10.1038/nrclinonc.2015.101
- Frosch Z, 2015, CL LYMPH MYELOM LEUK, V15, P92, DOI 10.1016/j.clml.2014.07.017
- Hoster E, 2008, BLOOD, V111, P558, DOI 10.1182/blood-2007-06-095331
- Hoster E, 2014, J CLIN ONCOL, V32, P1338, DOI 10.1200/JCO.2013.52.2466
- Howard OM, 2002, J CLIN ONCOL, V20, P1288, DOI 10.1200/JCO.20.5.1288
- Howlader N, 2015, SEER CANC STAT REV 1
- Juweid ME, 2005, J CLIN ONCOL, V23, P4652, DOI 10.1200/JCO.2005.01.891
- McKay P, 2012, BRIT J HAEMATOL, V159, P405, DOI 10.1111/bjh.12046
- Millennium Pharmaceuticals Inc, 2014, VELCADE BORT INJ SUB
- Pott C, 2010, BLOOD, V115, P3215, DOI 10.1182/blood-2009-06-230250
- Robak T, 2015, NEW ENGL J MED, V372, P944, DOI 10.1056/NEJMoa1412096
- Rummel MJ, 2013, LANCET, V381, P1203, DOI 10.1016/S0140-6736(12)61763-2
- Smith A, 2015, BRIT J CANCER, V112, P1575, DOI 10.1038/bjc.2015.94
- Zhou YH, 2008, CANCER, V113, P791, DOI 10.1002/cncr.23608